Novacyt S.a annual return on equity
2023
2024
2025
Novacyt S.a Return on Equity (ROE) Growth & History (NCYT)
Novacyt S.a's return on equity was −64.23% for fiscal 2025.
View full Novacyt S.a company overviewNovacyt S.a annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −64.23% | −2.42 pp |
| 2024 | 2024-12-31 | −61.81% | −33.86 pp |
| 2023 | 2023-12-31 | −27.95% | — |
Novacyt S.a return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Novacyt S.a's return on equity decreased from −27.95% to −64.23%, a change of −36.28 percentage points.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novacyt S.a source filings ↗Community posts
Novacyt grows sales but reports lower margins and reduced cash reserves
Novacyt ($NCYT) reported first-half revenue growth of 18% to £11.6 million, with approximately 9% underlying growth excluding acquired Southern Cross Diagnostics. Instrumentation sales increased about 30%, while clinical products grew more ...
